[
    [
        {
            "time": "",
            "original_text": "机构调研：云南白药、长安汽车受到机构关注",
            "features": {
                "keywords": [
                    "云南白药",
                    "长安汽车",
                    "机构关注"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "汽车"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "机构调研：云南白药、长安汽车受到机构关注",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "打新的懵了！最惨跌20％，又有新股上市首日破发！已有多个腰斩连续下跌",
            "features": {
                "keywords": [
                    "新股",
                    "破发",
                    "下跌"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "打新的懵了！最惨跌20％，又有新股上市首日破发！已有多个腰斩连续下跌",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "[天风Morning Call】晨会集萃20191112",
            "features": {
                "keywords": [
                    "晨会",
                    "天风证券"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[天风Morning Call】晨会集萃20191112",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 4,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "宋清辉：可转债发行流程较短融资更便利不少公司选择发行可转债",
            "features": {
                "keywords": [
                    "可转债",
                    "融资",
                    "发行流程"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "宋清辉：可转债发行流程较短融资更便利不少公司选择发行可转债",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "公司治理与经营业绩相得益彰 新华文轩荣获“最佳董事会奖”",
            "features": {
                "keywords": [
                    "新华文轩",
                    "最佳董事会奖",
                    "公司治理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "出版"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司治理与经营业绩相得益彰 新华文轩荣获“最佳董事会奖”",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中国抗体港交所上市！主要产品SM03已经进入Ⅲ期临床",
            "features": {
                "keywords": [
                    "中国抗体",
                    "港交所",
                    "上市",
                    "SM03",
                    "Ⅲ期临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国抗体港交所上市！主要产品SM03已经进入Ⅲ期临床",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "快讯：中国抗体今在港交所上市 股价跌幅扩大至14%",
            "features": {
                "keywords": [
                    "中国抗体",
                    "港交所",
                    "上市",
                    "股价跌幅"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "快讯：中国抗体今在港交所上市 股价跌幅扩大至14%",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "[IPO追踪】中国抗体制药：与云南白药在产品和市场上将有协同效应",
            "features": {
                "keywords": [
                    "中国抗体制药",
                    "云南白药",
                    "协同效应",
                    "IPO"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[IPO追踪】中国抗体制药：与云南白药在产品和市场上将有协同效应",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "297家药企业绩大比拼，有一家营收1406亿",
            "features": {
                "keywords": [
                    "药企",
                    "业绩",
                    "营收"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "297家药企业绩大比拼，有一家营收1406亿",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "香港本土首家生物科技类公司今日敲钟，中国抗体-B（3681.HK）上市股价每股7.6港元",
            "features": {
                "keywords": [
                    "中国抗体",
                    "生物科技",
                    "香港",
                    "上市",
                    "股价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "香港本土首家生物科技类公司今日敲钟，中国抗体-B（3681.HK）上市股价每股7.6港元",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]